<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38271479</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Cathelicidin peptide analogues inhibit EV71 infection through blocking viral entry and uncoating.</ArticleTitle><Pagination><StartPage>e1011967</StartPage><MedlinePgn>e1011967</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1011967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1011967</ELocationID><Abstract><AbstractText>Given the serious neurological complications and deaths associated with enterovirus 71 (EV71) infection, there is an urgent need to develop effective antivirals against this viral infection. In this study, we demonstrated that two Cathelicidin-derived peptides, LL-18 and FF-18 were more potent against EV71 infection than the parent peptide LL-37, which is the mature and processed form of Cathelicidin. These peptides could directly bind to the EV71 virus particles, but not to coxsackievirus, indicative of their high specificity. The binding of peptides with the virus surface occupied the viral canyon region in a way that could block virus-receptor interactions and inhibit viral uncoating. In addition, these peptide analogues could also relieve the deleterious effect of EV71 infection in vivo. Therefore, Cathelicidin-derived peptides might be excellent candidates for further development of antivirals to treat EV71 infection.</AbstractText><CopyrightInformation>Copyright: © 2024 Fan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biobank, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Haoyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xinrui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shangrui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaozhen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xun</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hongliang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3304-2683</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathogen Biology and Immunology, Xi'an Jiaotong University Health Science Center, Shaanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054804">Cathelicidins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054804" MajorTopicYN="N">Cathelicidins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>25</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>25</Day><Hour>13</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38271479</ArticleId><ArticleId IdType="pmc">PMC10846744</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1011967</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-23-01672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patterns of polymorphism and divergence in the VP1 gene of enterovirus 71 circulating in the Asia-Pacific region between 1994 and 2013. Journal of Virological Methods. 2013;193(2):713–28. doi: 10.1016/j.jviromet.2013.07.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.07.051</ArticleId><ArticleId IdType="pubmed">23933074</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–90. Epub 2010/10/22. doi: 10.1016/S1473-3099(10)70194-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li Y. Recent Progress on Functional Genomics Research of Enterovirus 71. Virol Sin. 2019;34(1):9–21. Epub 2018/12/16. doi: 10.1007/s12250-018-0071-9 ; PubMed Central PMCID: PMC6420560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-018-0071-9</ArticleId><ArticleId IdType="pmc">PMC6420560</ArticleId><ArticleId IdType="pubmed">30552635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan JJ, Shen L, Wu J, Zou XR, Gu JQ, Chen JG, et al.. Enterovirus A71 Proteins: Structure and Function. Frontiers in microbiology. 2018;9. ARTN 286 doi: 10.3389/fmicb.2018.00286 WOS:000425624100002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00286</ArticleId><ArticleId IdType="pmc">PMC5826392</ArticleId><ArticleId IdType="pubmed">29515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal Structure of Human Enterovirus 71. Science. 2012;336(6086):1274–. doi: 10.1126/science.1218713 WOS:000304905300037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Koike S. Cellular receptors for enterovirus A71. Journal of Biomedical Science. 2020;27(1). ARTN 23 doi: 10.1186/s12929-020-0615-9 WOS:000513548800001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-0615-9</ArticleId><ArticleId IdType="pmc">PMC6954530</ArticleId><ArticleId IdType="pubmed">31924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu KH, Diarimalala RO, Yao CG, Li HL, Wei YH. EV-A71 Mechanism of Entry: Receptors/Co-Receptors, Related Pathways and Inhibitors. Viruses-Basel. 2023;15(3). ARTN 785 doi: 10.3390/v15030785 WOS:000959765900001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030785</ArticleId><ArticleId IdType="pmc">PMC10051052</ArticleId><ArticleId IdType="pubmed">36992493</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, et al.. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science. 2015;347(6217):71–4. doi: 10.1126/science.1261962 WOS:000347102300050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261962</ArticleId><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth M, Pettitt T, Symonds A, Martin J. Identification of the pocket factors in a picornavirus. Archives of Virology. 2003;148(6):1225–33. doi: 10.1007/s00705-002-0974-4 WOS:000183722500016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-002-0974-4</ArticleId><ArticleId IdType="pubmed">12756627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XX, Peng W, Ren JS, Hu ZY, Xu JW, Lou ZY, et al.. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424–9. doi: 10.1038/nsmb.2255 WOS:000302514400010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG, He YN, Kuhn RJ. Picornavirus-receptor interactions. Trends in Microbiology. 2002;10(7):324–31. Pii S0966-842x(02)02383-1 doi: 10.1016/s0966-842x(02)02383-1 WOS:000176847300010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0966-842x(02)02383-1</ArticleId><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Huan YC, Kong Q, Mou HJ, Yi HX. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Frontiers in microbiology. 2020;11. ARTN 582779 doi: 10.3389/fmicb.2020.582779 WOS:000585623900001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.582779</ArticleId><ArticleId IdType="pmc">PMC7596191</ArticleId><ArticleId IdType="pubmed">33178164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al.. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951–9. doi: 10.1182/blood.v97.12.3951 WOS:000169164300042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.v97.12.3951</ArticleId><ArticleId IdType="pubmed">11389039</ArticleId></ArticleIdList></Reference><Reference><Citation>Findlay EG, Currie SM, Davidson DJ. Cationic Host Defence Peptides: Potential as Antiviral Therapeutics. Biodrugs. 2013;27(5):479–93. doi: 10.1007/s40259-013-0039-0 WOS:000324490900006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-013-0039-0</ArticleId><ArticleId IdType="pmc">PMC3775153</ArticleId><ArticleId IdType="pubmed">23649937</ArticleId></ArticleIdList></Reference><Reference><Citation>Alagarasu K, Patil PS, Shil P, Seervi M, Kakade MB, Tillu H, et al.. In-vitro effect of human cathelicidin antimicrobial peptide LL-37 on dengue virus type 2. Peptides. 2017;92:23–30. doi: 10.1016/j.peptides.2017.04.002 WOS:000402214100004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2017.04.002</ArticleId><ArticleId IdType="pubmed">28400226</ArticleId></ArticleIdList></Reference><Reference><Citation>Isogai E, Isogai H, Matuo K, Hirose K, Kowashi Y, Okumuara K, et al.. Sensitivity of genera Porphyromonas and Prevotella to the bactericidal action of C-terminal domain of human CAP18 and its analogues. Oral Microbiol Immun. 2003;18(5):329–32. doi: 10.1034/j.1399-302X.2003.00083.x WOS:000185088400012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-302X.2003.00083.x</ArticleId><ArticleId IdType="pubmed">12930528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Zhao X, Xun M, Ma C, Wang H. Reverse Genetic Approaches for the Generation of Full Length and Subgenomic Replicon of EV71 Virus. Frontiers in microbiology. 2021;12:665879. Epub 2021/06/08. doi: 10.3389/fmicb.2021.665879 ; PubMed Central PMCID: PMC8172962.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.665879</ArticleId><ArticleId IdType="pmc">PMC8172962</ArticleId><ArticleId IdType="pubmed">34093481</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Tang Q, Xu T, Cai Y, Lei P, Chen Y, et al.. Discovery of aminothiazole derivatives as novel human enterovirus A71 capsid protein inhibitors. Bioorg Chem. 2022;122:105683. Epub 2022/03/13. doi: 10.1016/j.bioorg.2022.105683 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2022.105683</ArticleId><ArticleId IdType="pubmed">35278779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Zhao Y, Kotecha A, Fry EE, Kelly JT, Wang X, et al.. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nature microbiology. 2019;4(3):414–9. doi: 10.1038/s41564-018-0319-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0319-z</ArticleId><ArticleId IdType="pubmed">30531980</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang MH, Wang XX, Wang Q, Wang YX, Lin JP, Sun Y, et al.. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5(9):692–703. doi: 10.1007/s13238-014-0087-3 WOS:000342123400006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0087-3</ArticleId><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS. Annexin II Binds to Capsid Protein VP1 of Enterovirus 71 and Enhances Viral Infectivity. Journal of virology. 2011;85(22):11809–20. doi: 10.1128/JVI.00297-11 WOS:000296422700025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. P Natl Acad Sci USA. 2013;110(14):5463–7. doi: 10.1073/pnas.1222379110 WOS:000318037800054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222379110</ArticleId><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, et al.. The Site of Attachment in Human Rhinovirus-14 for Antiviral Agents That Inhibit Uncoating. Science. 1986;233(4770):1286–93. doi: 10.1126/science.3018924 WOS:A1986D943800024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3018924</ArticleId><ArticleId IdType="pubmed">3018924</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Y, Jesudhasan PR, Aguilera ER, Pfeiffer JK. Identification and Characterization of a Poliovirus Capsid Mutant with Enhanced Thermal Stability. Journal of virology. 2019;93(6). Epub 2018/12/21. doi: 10.1128/JVI.01510-18 ; PubMed Central PMCID: PMC6401428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01510-18</ArticleId><ArticleId IdType="pmc">PMC6401428</ArticleId><ArticleId IdType="pubmed">30567995</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister S, Prunotto A, Dal Peraro M, Kohn T. Salt Enhances the Thermostability of Enteroviruses by Stabilizing Capsid Protein Interfaces. Journal of virology. 2020;94(11). Epub 2020/03/28. doi: 10.1128/JVI.02176-19 ; PubMed Central PMCID: PMC7269450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02176-19</ArticleId><ArticleId IdType="pmc">PMC7269450</ArticleId><ArticleId IdType="pubmed">32213614</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. Journal of Virology. 2013;87(6):3335–47. doi: 10.1128/JVI.02070-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nature Medicine. 2009;15(7):794–7. doi: 10.1038/nm.1961</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al.. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. Journal of virology. 2004;78(15):7916–24. doi: 10.1128/JVI.78.15.7916-7924.2004 WOS:000222755600007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014;2. ARTN 62 doi: 10.3389/fchem.2014.00062 WOS:000209678600065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2014.00062</ArticleId><ArticleId IdType="pmc">PMC4126357</ArticleId><ArticleId IdType="pubmed">25152873</ArticleId></ArticleIdList></Reference><Reference><Citation>Cathal O’Brien DRF, Conleth Feighery. Peptide length significantly influences in vitro affinity for MHC class II molecules. Immunome research. 2008;4(6). doi: 10.1186/1745-7580-4-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-7580-4-6</ArticleId><ArticleId IdType="pmc">PMC2640366</ArticleId><ArticleId IdType="pubmed">19036163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay D, Zambon M. Antiviral drug resistance. BMJ. 1998;317(7159):660–2. Epub 1998/09/04. doi: 10.1136/bmj.317.7159.660 ; PubMed Central PMCID: PMC1113839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.317.7159.660</ArticleId><ArticleId IdType="pmc">PMC1113839</ArticleId><ArticleId IdType="pubmed">9728000</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin KK, Renzette N, Kowalik TF, Jensen JD. Antiviral drug resistance as an adaptive process. Virus Evol. 2016;2(1):vew014. Epub 2017/07/12. doi: 10.1093/ve/vew014 ; PubMed Central PMCID: PMC5499642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/vew014</ArticleId><ArticleId IdType="pmc">PMC5499642</ArticleId><ArticleId IdType="pubmed">28694997</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Kung YA, Shih SR. Antivirals and vaccines for Enterovirus A71. Journal of Biomedical Science. 2019;26(1). ARTN 65 doi: 10.1186/s12929-019-0560-7 WOS:000483770800001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0560-7</ArticleId><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalani S, Gew LT, Poh CL. Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease. Peptides. 2021;136. ARTN 170443 doi: 10.1016/j.peptides.2020.170443 WOS:000614690400008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2020.170443</ArticleId><ArticleId IdType="pmc">PMC7648656</ArticleId><ArticleId IdType="pubmed">33171280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang NX, Zhang WP, Cheng XR, Yan ZB, Shao G, et al.. Therapeutic peptides: current applications and future directions. Signal Transduct Tar. 2022;7(1). ARTN 48 doi: 10.1038/s41392-022-00904-4 WOS:000755124600001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00904-4</ArticleId><ArticleId IdType="pmc">PMC8844085</ArticleId><ArticleId IdType="pubmed">35165272</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Dai Y, Fu YX, Wang KZ, Yang Y, Li M, et al.. Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding. Antivir Res. 2021;187. ARTN 105021 doi: 10.1016/j.antiviral.2021.105021 WOS:000657777900004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105021</ArticleId><ArticleId IdType="pubmed">33508330</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura K, Itoh A, Isogai E, Hirose K, Hosokawa Y, Abiko Y, et al.. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett. 2004;212(2):185–94. Epub 2004/07/29. doi: 10.1016/j.canlet.2004.04.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2004.04.006</ArticleId><ArticleId IdType="pubmed">15279899</ArticleId></ArticleIdList></Reference><Reference><Citation>Isogai E, Isogai H, Matuo K, Hirose K, Hirata M. Sensitivity of genera Porphyromonas and Prevotella to the bactericidal action of C-terminal domain of human CAP18 and its analogues. Molecular Oral Microbiology. 2010;18(5):329–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12930528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda K, Fukuda T, Yoneyama H, Katayama M, Isogai H, Okumura K, et al.. Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53+/+ and p53. Oncol Rep. 2012;28(3):829–34. Epub 2012/06/28. doi: 10.3892/or.2012.1876 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2012.1876</ArticleId><ArticleId IdType="pubmed">22736062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda K, Okumura K, Isogai H, Isogai E. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol. 2015;5. ARTN 144 doi: 10.3389/fonc.2015.00144 WOS:000359148400001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2015.00144</ArticleId><ArticleId IdType="pmc">PMC4485164</ArticleId><ArticleId IdType="pubmed">26175965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaini Z, McMinn P. A single mutation in capsid protein VP1 (Q145E) of a genogroup C4 strain of human enterovirus 71 generates a mouse-virulent phenotype. J Gen Virol. 2012;93(Pt 9):1935–40. Epub 2012/06/01. doi: 10.1099/vir.0.043893-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.043893-0</ArticleId><ArticleId IdType="pubmed">22647370</ArticleId></ArticleIdList></Reference><Reference><Citation>Victorio CB, Xu Y, Ng Q, Meng T, Chow VT, Chua KB. Cooperative effect of the VP1 amino acids 98E, 145A and 169F in the productive infection of mouse cell lines by enterovirus 71 (BS strain). Emerg Microbes Infect. 2016;5(6):e60. Epub 2016/06/23. doi: 10.1038/emi.2016.56 ; PubMed Central PMCID: PMC4932649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.56</ArticleId><ArticleId IdType="pmc">PMC4932649</ArticleId><ArticleId IdType="pubmed">27329847</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS. American Journal of Epidemiology. 1938.</Citation></Reference><Reference><Citation>Zhao X, Yuan H, Yang H, Liu Y, Xun M, Li X, et al.. N-Acetyltransferase 8 Promotes Viral Replication by Increasing the Stability of Enterovirus 71 Nonstructural Proteins. Journal of virology. 2022:jvi0011922. Epub 2022/02/17. doi: 10.1128/jvi.00119-22 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00119-22</ArticleId><ArticleId IdType="pmc">PMC8941898</ArticleId><ArticleId IdType="pubmed">35170979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, et al.. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother. 2004;48(9):3523–9. Epub 2004/08/26. doi: 10.1128/AAC.48.9.3523-3529.2004 ; PubMed Central PMCID: PMC514779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>